(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte ...
Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ: OMER) today ...
SEATTLE, January 27, 2026--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed ...
Health on MSN
What's the life expectancy for complement 3 glomerulopathy—and how does it affect quality of life?
Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the kidneys. The prognosis and life expectancy for C3G depends on the disease ...
Investing.com -- Omeros Corporation (NASDAQ:OMER) stock rose 3.1% on Tuesday after the company announced it has completed its first commercial shipments of YARTEMLEA (narsoplimab-wuug) to distributors ...
Costa Mesa, California - February 10, 2026 - PRESSADVANTAGE - Arthritis is one of the most common chronic mobility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results